[Market Focus] GC Pharma Jumps 7% on News of ALYGLO's Inclusion in Formularies of Three Major U.S. Insurers

GC Pharma shares are up more than 7% following news that its blood product 'ALYGLO' has been included in the formularies of three major U.S. insurance companies.

As of 9:59 a.m. on September 10, GC Pharma is trading at 158,700 won, up 7.59% (11,200 won) from the previous trading day.

On this day, GC Pharma announced that its blood product 'ALYGLO' has been listed in the formularies of three major U.S. insurance companies: Cigna Healthcare, United Healthcare, and Blue Cross Blue Shield.

ALYGLO received approval from the U.S. Food and Drug Administration (FDA) in December 2023, and since August 10, 2024, it has been administered to American patients with primary immunodeficiency.

Lee Sunkyung, a researcher at SK Securities, stated in a recent report, "With the inclusion of ALYGLO in the formularies of major pharmacy benefit managers (PBMs) such as Cigna, which is crucial for penetrating the U.S. market, GC Pharma's consolidated annual performance this year is expected to reach sales of 1.7423 trillion won and operating profit of 57.1 billion won, representing increases of 7.1% and 65.8%, respectively, compared to the previous year."